Cargando…
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis
Antiangiogenic therapy is a recognized method for countering the immunosuppressive tumor microenvironment (TME) and improving anti-tumor immunity. PB101 is a glycosylated decoy receptor that binds to VEGF-A and PlGF with high affinity, based on the VEGFR1 backbone. Here, we elucidated PB101-induced...
Autores principales: | Go, Eun-Jin, Yang, Hannah, Lee, Seung Joon, Yang, Hyun Gul, Shin, Jin A., Lee, Won Suk, Lim, Hye Seong, Chon, Hong Jae, Kim, Chan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515676/ https://www.ncbi.nlm.nih.gov/pubmed/37744990 http://dx.doi.org/10.1080/2162402X.2023.2259212 |
Ejemplares similares
-
PlGF, immune system and hypertension
por: Carnevale, Daniela, et al.
Publicado: (2015) -
Concentrations of VEGF and PlGF Decrease in Eyes After Intravitreal Conbercept Injection
por: Zhou, Jun, et al.
Publicado: (2018) -
Physical activity differentially regulates VEGF, PlGF, and their receptors in the human placenta
por: Bhattacharjee, Jayonta, et al.
Publicado: (2021) -
PlGF Immunological Impact during Pregnancy
por: Albonici, Loredana, et al.
Publicado: (2020) -
A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome
por: Stepan, H., et al.
Publicado: (2016)